§ 01
What Are IV Lidocaine Infusions?
IV Lidocaine Infusion
Overview DiagramIntravenous lidocaine infusion therapy delivers the well-known local anesthetic lidocaine systemically through an IV drip. At sub-toxic plasma concentrations (2–5 mcg/mL), lidocaine exerts powerful analgesic, anti-inflammatory, and neuroprotective effects that extend far beyond its local anesthetic action. This systemic approach allows lidocaine to reach voltage-gated sodium channels and NMDA receptors throughout the central nervous system.
It is critical to understand that IV lidocaine therapy is NOT the same as topical lidocaine patches or local lidocaine injections. Topical and injected lidocaine act locally at the site of application, blocking peripheral nerve transmission. IV lidocaine, by contrast, achieves systemic distribution and crosses the blood-brain barrier, directly modulating pain processing circuits in the spinal cord and brainstem. This central mechanism is what allows it to address widespread pain and central sensitization — conditions that localized treatments cannot effectively reach.
IV lidocaine targets the central nervous system directly — resetting amplified pain circuits that topical and local treatments cannot reach.
The use of IV lidocaine for chronic pain was first reported in the 1960s and has been studied extensively in neuropathic, post-surgical, and inflammatory pain conditions. Its application in chronic myofascial pain syndrome is more recent, driven by the recognition that many MPS patients develop central sensitization — a pathophysiological state where the central nervous system amplifies pain signals beyond what the peripheral input would normally generate.
§ 02
Mechanism of Action
IV lidocaine exerts its analgesic effects through four distinct but complementary mechanisms. Unlike topical or injected lidocaine, the systemic route delivers the drug to the central nervous system, enabling direct modulation of spinal cord and brainstem pain processing circuits.
Systemic Sodium Channel Blockade
Intravenous lidocaine blocks voltage-gated sodium channels (Nav1.7, Nav1.8) throughout the peripheral and central nervous system. These channels are upregulated in chronic pain states. Systemic blockade reduces ectopic firing in sensitized nociceptors and dorsal horn neurons, interrupting the amplified pain signaling characteristic of central sensitization.
Central Sensitization Reset
Chronic MPS leads to wind-up and central sensitization — a state where the spinal cord and brain amplify pain signals. IV lidocaine crosses the blood-brain barrier at sub-toxic doses and directly modulates hyperexcitable dorsal horn neurons. This systemic effect can "reset" central pain processing in a way that topical or local lidocaine cannot achieve.
Anti-Inflammatory Effects
Beyond its anesthetic properties, IV lidocaine exerts significant anti-inflammatory effects through suppression of pro-inflammatory cytokines including TNF-alpha, IL-6, and IL-1 beta. It also inhibits neutrophil priming and migration, reduces reactive oxygen species production, and modulates NF-kB signaling — collectively reducing the neuroinflammatory milieu that sustains chronic myofascial trigger points.
NMDA Receptor Modulation
Lidocaine acts as a non-competitive antagonist at NMDA (N-methyl-D-aspartate) receptors, which play a critical role in the development and maintenance of central sensitization and wind-up phenomena. NMDA receptor blockade reduces excitatory neurotransmission in the spinal cord dorsal horn, complementing the sodium channel effects to provide multi-target pain modulation.
How IV Lidocaine Infusions Work
Sodium Channel Blockade
Systemic blockade of Nav1.7 and Nav1.8 channels reduces ectopic firing in sensitized nociceptors throughout the nervous system.
Central Sensitization Reset
Crosses the blood-brain barrier to modulate hyperexcitable dorsal horn neurons, reducing amplified pain signaling.
Anti-Inflammatory Action
Suppresses TNF-alpha, IL-6, and IL-1 beta production, reducing the neuroinflammatory environment sustaining chronic trigger points.
NMDA Receptor Modulation
Non-competitive NMDA antagonism reduces excitatory neurotransmission contributing to wind-up and central sensitization.
§ 03
Infusion Protocol
Dosing Range
1–5 mg/kg/hrThe infusion rate is titrated based on patient weight and clinical response. Most protocols begin at 1–2 mg/kg/hr and increase gradually. Cumulative doses typically range from 3–5 mg/kg per session. Higher rates are used only in experienced centers with full monitoring capability.
Infusion Duration
1–4 hoursA typical infusion session lasts 1 to 4 hours depending on the protocol, dose, and patient tolerance. Shorter infusions (1–2 hours) are common for initial sessions; longer infusions may be used once safety is established. Some centers use overnight infusions for refractory cases.
Number of Infusions
3–6 sessionsA standard treatment course involves 3 to 6 infusions administered weekly or biweekly. Some patients respond after 2–3 sessions; others require the full course. Maintenance infusions every 4–8 weeks may be needed to sustain benefit in chronic cases.
Monitoring Requirements
Continuous cardiac monitoringPatients require IV access, continuous ECG monitoring, pulse oximetry, and blood pressure measurement throughout the infusion and for at least 30 minutes afterward. A crash cart with lipid emulsion (Intralipid 20%) must be immediately available for local anesthetic systemic toxicity (LAST) rescue.
Setting
Monitored clinical environmentIV lidocaine infusions must be administered in a monitored setting — typically an infusion suite, procedural area, or hospital outpatient unit. The treating physician must be credentialed in ACLS and LAST management. Patients should not drive for 2 hours after the infusion.
Pre-Infusion Assessment
ECG, hepatic function, medication reviewA baseline 12-lead ECG is required to rule out conduction abnormalities (heart block, prolonged QTc). Hepatic function tests are necessary because lidocaine is primarily metabolized by the liver (CYP3A4, CYP1A2). A thorough medication review is critical to identify drugs that may increase lidocaine levels or cardiac risk.
§ 04
Clinical Evidence
Moderate EvidenceChronic neuropathic and centralized myofascial pain
Systematic Reviews — Chronic Pain
Systematic reviews of systemic local-anaesthetic-type drugs for chronic pain describe modest, often short-lived pain relief compared with placebo, with the caveat that included trials are heterogeneous and generally small. Reviewers consistently call for larger, better-designed RCTs.
Systematic Reviews — Neuropathic Pain
Systematic reviews suggest that IV lidocaine can produce short- to medium-term pain relief in selected neuropathic pain states. The relatively stronger signals are reported in post-surgical and diabetic neuropathy populations, with the evidence in centralized conditions such as fibromyalgia and widespread MPS still limited and emerging.
Trials — Widespread / Centralized Pain
Small trials and case series have explored IV lidocaine in widespread or centrally amplified pain presentations and report variable degrees of short-term pain reduction in a subset of responders. Specific average pain-reduction figures vary substantially across studies and should not be presented as a single, dependable number.
Fibromyalgia & Central Sensitization Studies
Studies in fibromyalgia — which shares pathophysiologic mechanisms with centralized MPS — demonstrate that IV lidocaine responders can be identified by the presence of central sensitization features. These studies support a mechanistic rationale for targeting the sodium channel-mediated component of central pain amplification.
Comparative & Mechanistic Studies
Head-to-head comparisons and mechanistic studies indicate that IV lidocaine provides benefits beyond what topical lidocaine can achieve, attributable to its systemic effect on central nervous system sodium channels and NMDA receptors. This distinguishes it as a centrally-acting analgesic intervention rather than a simple local anesthetic.
Pain Score Reduction
Variable reduction in VAS/NRS reported in responders with central sensitization features
Central Sensitization
Strongest evidence in patients with CSI > 40 and widespread allodynia
Duration of Benefit
Pain relief lasting weeks to months after a treatment course
§ 05
The Infusion Session
Pre-Infusion Assessment
Review baseline ECG, vital signs, hepatic function, and current medications. Confirm absence of contraindications. Obtain informed consent covering risks of cardiac arrhythmia, seizure, and local anesthetic systemic toxicity (LAST).
IV Access & Monitoring Setup
Establish peripheral IV access. Attach continuous cardiac monitoring (ECG), pulse oximetry, and automated blood pressure cuff. Confirm crash cart availability with Intralipid 20% lipid emulsion readily accessible.
Infusion Initiation
Begin the lidocaine infusion at a low rate (typically 1 mg/kg/hr) using an infusion pump for precise delivery. Monitor the patient closely during the first 15 minutes for any signs of CNS or cardiac toxicity — perioral numbness, tinnitus, dizziness, or ECG changes.
Dose Titration
Gradually increase the infusion rate based on patient tolerance and clinical protocol, up to the target dose (usually 3–5 mg/kg/hr). Continue monitoring vital signs and cardiac rhythm at regular intervals throughout. Reduce the rate or stop the infusion immediately if toxicity signs develop.
Ongoing Monitoring & Assessment
Throughout the infusion, assess pain levels, neurological status, and vital signs at regular intervals (typically every 15–30 minutes). Ask specifically about perioral tingling, metallic taste, visual changes, tinnitus, or dizziness — these are early warning signs of lidocaine toxicity.
Post-Infusion Observation
After the infusion is complete, continue monitoring for at least 30 minutes. Assess pain scores, neurological function, and hemodynamic stability before discharge. Instruct the patient not to drive for at least 2 hours. Document the response and any adverse effects for future dosing adjustments.
§ 06
Ideal Candidates
Widespread MPS with Central Sensitization
Patients whose myofascial pain has evolved beyond a localized trigger point problem to a widespread pain syndrome with features of central sensitization — allodynia, hyperalgesia, wind-up pain, and pain that extends beyond expected trigger point referral patterns. These patients have the highest likelihood of meaningful benefit from systemic sodium channel blockade.
Failed Multiple Local Treatments
Patients who have undergone an adequate trial of local therapies — including dry needling, trigger point injections, manual therapy, and physical rehabilitation — without sustained improvement. IV lidocaine addresses the systemic and central components of pain that local treatments cannot reach.
High Pain Catastrophizing Scores
Patients with elevated pain catastrophizing, kinesiophobia, and central sensitization inventories (CSI > 40) often have a significant central component to their pain. The central action of IV lidocaine can modulate the amplified pain processing that contributes to catastrophizing.
Chronic MPS with Comorbid Neuropathic Features
Patients whose myofascial pain syndrome overlaps with neuropathic pain — burning, shooting, electric-shock qualities, or numbness — suggesting peripheral nerve sensitization. IV lidocaine is well-suited for mixed nociceptive-neuropathic pain presentations.
Patients Seeking Opioid Reduction
IV lidocaine can serve as part of a multimodal analgesic strategy aimed at reducing opioid dependence in chronic MPS patients. The multi-target mechanism (sodium channels, NMDA receptors, anti-inflammatory) provides broad-spectrum pain relief that may enable meaningful opioid dose reduction.
§ 07
Contraindications & Side Effects
Absolute Contraindications
Relative Contraindications
Side Effects
Requires Monitoring
Side effects of IV lidocaine are dose-dependent and generally mild at therapeutic infusion rates. Serious adverse events (seizures, cardiac arrhythmia) are rare when proper protocols and monitoring are followed, but the risk mandates continuous cardiac monitoring and immediate access to resuscitation equipment.
Perioral Numbness / Tingling
A common side effect during infusion. Perioral numbness and tongue tingling are typical at therapeutic levels and are not cause for alarm unless they progress to more severe symptoms.
Lightheadedness / Dizziness
Mild lightheadedness is common during the infusion and usually resolves shortly after completion. It reflects the central nervous system effects of lidocaine at therapeutic concentrations.
Metallic Taste
A metallic or unusual taste in the mouth is a frequent benign side effect of IV lidocaine. While harmless, a sudden onset of metallic taste during dose escalation may indicate approaching therapeutic ceiling.
Tinnitus
Ringing or buzzing in the ears can occur at higher infusion rates. Tinnitus is an early warning sign of approaching toxic levels and should prompt a reduction in infusion rate or temporary pause.
Nausea
Mild nausea may occur during infusion, particularly at higher doses. It typically resolves with a small reduction in infusion rate. Anti-emetics are rarely needed.
Drowsiness
Mild somnolence is common and reflects the central sedative effect of lidocaine. This is why patients are instructed not to drive for at least 2 hours after the infusion.
§ 08
IV Lidocaine vs Other Treatments
Comparison
IV Lidocaine AdvantageIV Lidocaine Limitation
vs Topical Lidocaine (Patches/Cream)
Systemic effect reaches central nervous system; treats central sensitization
Requires IV access, monitoring, and clinical setting; higher risk profile
vs Trigger Point Injections
Addresses central and widespread pain beyond individual trigger points
Does not treat specific trigger points directly; more resource-intensive
vs Ketamine Infusions
Better side effect profile; no dissociative effects; no abuse potential
May be less effective for severe central sensitization in some patients
vs Oral Mexiletine
Higher bioavailability and controlled delivery via IV route
Cannot be self-administered; requires clinical visits for each infusion
§ 09
Expected Timeline
3–6
Treatment SessionsA standard course of 3 to 6 infusions administered weekly or biweekly
1–2 Wk
Between SessionsWeekly to biweekly intervals allow assessment of cumulative response
Wks–Mo
Duration of BenefitPain relief often persists for weeks to months beyond the infusion course, particularly in central sensitization responders
Key Takeaways
IV lidocaine infusions deliver systemic sodium channel blockade that reaches the central nervous system — this is fundamentally different from topical or injected lidocaine.
The mechanism involves four complementary pathways: Nav1.7/Nav1.8 blockade, central sensitization reset, anti-inflammatory cytokine suppression, and NMDA receptor modulation.
Best candidates are patients with widespread MPS, central sensitization features (allodynia, hyperalgesia, CSI > 40), and failure of local treatments.
Existing evidence comes mostly from small trials and systematic reviews; reported pain reductions vary across studies, and benefit is most plausible in selected centralized phenotypes rather than guaranteed across MPS broadly.
CRITICAL: Continuous cardiac monitoring is mandatory. Contraindicated in heart block and severe liver disease. Crash cart with lipid emulsion must be immediately available.
Typical protocol: 1–5 mg/kg/hr over 1–4 hours, with 3–6 sessions. Must be performed in a monitored clinical setting by ACLS-credentialed physicians.
IV lidocaine is not a first-line therapy — it is reserved for centralized, refractory myofascial pain that has failed conventional local treatments.